Raj Rai Archives - CDR – Chain Drug Review

Fresenius Kabi to buy Akorn for $4.3 billion

April 24, 2017 by Chain Drug Review Akorn, Fresenius Kabi, John Ducker, Raj Rai Business, Pharmacy, Supplier News

LAKE ZURICH, Ill., and LAKE FOREST, Ill. — Global health care company Fresenius Kabi plans to acquire U.S. prescription and over-the-counter drug maker Akorn for $4.3 billion. Under the deal, announced late Monday, Fresenius Kabi agreed to buy Akorn $34 per share, plus the assume about $450 million of debt. The U.S. headquarters for Akorn

Akorn adds to executive team

April 28, 2015 by Chain Drug Review and Chain Drug Review Akorn, Jaspreet Gill, Jonathan Kafer, Raj Rai, Randall Pollard, Steve Lichter Supplier News

LAKE FOREST, Ill. — Akorn Inc. has announced four appointments to its management team, including a new sales and marketing leader. The specialty generic pharmaceutical company said Monday that Jonathan Kafer has been hired as executive vice president of sales and marketing, a newly created position. In the role, he will oversee all commercial functions for Akorn’s business units, as well as play an